Thursday, July 30, 2026

Medical Debt Soars, Despite 340B Purchases Passing $100 Billion

›
By: Marcus J. Hopkins , Health Policy Lead Consultant, ADAP Advocacy Drug purchases under the 340B Drug Pricing Program exceeded $100 billio...
Thursday, July 23, 2026

Insurers Regularly Delay, Deny, and Defend Their Treatment Malfeasance

›
By: Marcus J. Hopkins , Health Policy Lead Consultant, ADAP Advocacy New research conducted by Johns Hopkins Bloomberg School of Public Heal...
Thursday, July 16, 2026

Co-Pay Accumulators Are a Craven Attempt to Accumulate Profit Off the Backs of Patients

›
By: Marcus J. Hopkins , Health Policy Lead Consultant, ADAP Advocacy Imagine, for a moment, going to a restaurant and paying for your meal w...
Thursday, July 9, 2026

The Opacity Behind the 340B-Eligible Hospital Transparency

›
By: Marcus J. Hopkins , Health Policy Lead Consultant, ADAP Advocacy What happens when one of the only ways a 340B Drug Pricing Program-eli...
1 comment:
Thursday, July 2, 2026

Extraction Dressed Up as Care: Why the 340B Program Needs to Answer to Patients

›
By: Ryan Alvey, Executive Director & Founder, Positive Change Movement, and member of the ADAP Advocacy 340B Patient Advisory Committee ...
Thursday, June 25, 2026

New House Bill Would Require Insurers to Count Direct-to-Consumer Drug Purchases

›
By: Marcus J. Hopkins , Health Policy Lead Consultant, ADAP Advocacy A bill introduced by Representative Greg Murphy, M.D. (R-NC-03), would ...